Patents by Inventor Eric First
Eric First has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230014170Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: ApplicationFiled: September 20, 2022Publication date: January 19, 2023Applicant: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Patent number: 11478431Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: GrantFiled: June 16, 2020Date of Patent: October 25, 2022Assignee: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Publication number: 20220264926Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.Type: ApplicationFiled: March 1, 2022Publication date: August 25, 2022Applicant: Alcresta Therapeutics, Inc.Inventors: Eric FIRST, David BROWN, Albert Archie STONE
-
Patent number: 11291236Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.Type: GrantFiled: September 6, 2018Date of Patent: April 5, 2022Assignee: Alcresta Therapeutics, Inc.Inventors: Eric First, David Brown, Albert Archie Stone
-
Publication number: 20210259924Abstract: Exemplary embodiments of the disclosure may be drawn to a device having a vessel configured to contain a source of lipids and a chamber fluidly connected to an outlet of the vessel. The chamber may contain immobilized lipase positioned within a flow path in the chamber along which the lipids flow when released from the vessel into the chamber. The device may also include an outlet through which the lipids flow after passing through the chamber.Type: ApplicationFiled: May 11, 2021Publication date: August 26, 2021Applicant: Alcresta Therapeutics, Inc.Inventors: Eric FIRST, David Widom
-
Patent number: 11045396Abstract: Exemplary embodiments of the disclosure may be drawn to a device having a vessel configured to contain a source of lipids and a chamber fluidly connected to an outlet of the vessel. The chamber may contain immobilized lipase positioned within a flow path in the chamber along which the lipids flow when released from the vessel into the chamber. The device may also include an outlet through which the lipids flow after passing through the chamber.Type: GrantFiled: August 15, 2018Date of Patent: June 29, 2021Assignee: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Publication number: 20200306196Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: ApplicationFiled: June 16, 2020Publication date: October 1, 2020Applicant: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Patent number: 10716761Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: GrantFiled: July 23, 2018Date of Patent: July 21, 2020Assignee: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Publication number: 20190075835Abstract: Exemplary embodiments of the disclosure may be drawn to a device having one or more chambers. The one or more chambers may contain immobilized lipase and a phytosterol processing excipient. The device may also include an inlet fluidly connected to one of the one or more chambers, wherein the inlet is configured to receive nutritional formula into one of the one or more chambers. The device may further include an outlet through which nutritional formula is configured to flow after passing through the one or more chambers.Type: ApplicationFiled: September 6, 2018Publication date: March 14, 2019Applicant: Alcresta Therapeutics, Inc.Inventors: Eric FIRST, David Widom, Albert Archie Stone, Willem Robert Klass Schoevaart, Michiel Christian Alexander van Vliet
-
Publication number: 20190075830Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.Type: ApplicationFiled: September 6, 2018Publication date: March 14, 2019Applicant: Alcresta Therapeutics, Inc.Inventors: Eric FIRST, David Brown, Albert Archie Stone
-
Publication number: 20190053987Abstract: Exemplary embodiments of the disclosure may be drawn to a device having a vessel configured to contain a source of lipids and a chamber fluidly connected to an outlet of the vessel. The chamber may contain immobilized lipase positioned within a flow path in the chamber along which the lipids flow when released from the vessel into the chamber. The device may also include an outlet through which the lipids flow after passing through the chamber.Type: ApplicationFiled: August 15, 2018Publication date: February 21, 2019Applicant: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Publication number: 20190022015Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: ApplicationFiled: July 23, 2018Publication date: January 24, 2019Applicant: Alcresta Therapeutics, Inc.Inventors: Eric FIRST, David Widom
-
Patent number: 9777309Abstract: A method of conducting an enzymatic reaction assay involving adenosine 5?-monophosphate (AMP) comprising the steps of reacting one or more compounds and producing AMP, deaminating the AMP to produce IMP, and oxidating the IMP by NAD+ to produce XMP and NADH.Type: GrantFiled: October 6, 2015Date of Patent: October 3, 2017Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Eric A First, Charles J Richardson
-
Publication number: 20160097075Abstract: A method of conducting an enzymatic reaction assay involving adenosine 5?-monophosphate (AMP) comprising the steps of reacting one or more compounds and producing AMP, deaminating the AMP to produce IMP, and oxidating the IMP by NAD+ to produce XMP and NADH.Type: ApplicationFiled: October 6, 2015Publication date: April 7, 2016Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Eric A FIRST, Charles J RICHARDSON
-
Patent number: 8871224Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.Type: GrantFiled: March 28, 2011Date of Patent: October 28, 2014Assignee: Allergan, Inc.Inventor: Eric First
-
Publication number: 20110206731Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.Type: ApplicationFiled: March 28, 2011Publication date: August 25, 2011Applicant: ALLERGAN, INC.Inventor: Eric FIRST
-
Publication number: 20080050404Abstract: Methods for treating a pressure sore or for preventing development of a pressure sore by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a pressure sore or to a pressure point, or to the vicinity thereof.Type: ApplicationFiled: October 31, 2007Publication date: February 28, 2008Inventor: Eric First
-
Publication number: 20080014159Abstract: Methods for treating melanin related afflictions by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a melanin related affliction.Type: ApplicationFiled: July 17, 2007Publication date: January 17, 2008Applicant: ALLERGAN, INC.Inventor: ERIC FIRST
-
Publication number: 20080003242Abstract: Methods for treating kinesia (motion sickness) by local administration of a Clostridial toxin, such as a botulinum toxin, to a cranial or neck area of a patient susceptible to motion sickness.Type: ApplicationFiled: August 9, 2007Publication date: January 3, 2008Applicant: ALLERGAN, INC.Inventor: ERIC FIRST
-
Publication number: 20070160633Abstract: The present invention relates to methods for enhancing the therapeutic effects of a neurotoxin, e.g., a botulinum toxin, where the methods comprise a “wash-down” (e.g., a decreased intake) of a current pain medication and an administration of a neurotoxin. In some embodiments, the present inventions relates to methods for enhancing the therapeutic effects of a neurotoxin for treating pain, e.g., headache pain.Type: ApplicationFiled: January 12, 2006Publication date: July 12, 2007Applicant: ALLERGAN, INC.Inventors: Eric First, Ryan Irvine